This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Air Force/Texas Coronary Atherosclerosis Prevention study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • randomized controlled trial that enrolled 5608 men (aged 45-73) and 997 postmenopausal women (aged 55-73) with average LDL and total cholesterol levels. The mean total cholesterol for the trial group was 5.71 mmol/l.
  • patients were randomized to lovostatin (20-40mg daily) or placebo in addition to a low cholesterol, low saturated fat diet
  • after an average follow-up of 5.2 years
    • the lovostatin group showed a significant reduction in incidence of acute major coronary events (by 37%), unstable angina (325) and myocardial infarctions (40%).
    • the beneficial effects of lovostatin therapy were evident after only one year of the study.
    • lovostatin group showed a reduction in LDL cholesterol by 25% and an increase in HDL cholesterol by 6%

  • Conclusions - lovostatin therapy reduced the risk of acute coronary artery events in a trial group with average total and LDL-cholesterols.Treatment benefits were apparent in men and women.

Reference:

  • JAMA (1998), 279, 1615-22.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.